Pfizer Corporation

Pharmacia & Upjohn Company

Christopher Phillips

John Paul Mathias

Russell Andrew Lewthwaite

David Simon Millan

John Nicholas Freskos

David Louis Brown

Yvette M Fobian

Michael B Tollefson

Andrew Simon Bell

Robert Owen Hughes

Dafydd Rhys Owen

Brent V Mischke

Michael John Palmer

E Jon Jacobsen

Todd M Maddux

David Graham Brown

John M Molyneaux

John K Walker

Joseph B Moon

Steven E Heasley

D Joseph Rogier, Jr

A compound of formula (I), or a pharmaceutical acceptable salt and/or solvate (including hydrate) thereof; and the use of a compound of formula (I) in the treatment of a TNF-mediated disease, disorder, or condition, or a p38-mediated disease, disorder, or condition, in particular the allergic and non-allergic airways diseases, more particularly obstructive or inflammatory airways diseases, preferably chronic obstructive pulmonary disease.

Triazolopyridinylsulfanyl derivatives as P38 map kinase inhibitors

Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I: wherein R, R, Rand Rare as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, synthetic methods, and intermediates are also disclosed.

Pyridine [3,4-b] pyrazinones

A compound of formula (I), or a pharmaceutically acceptable salt and/or solvate (including hydrate) thereof; and the use of a compound of formula (I) in the treatment of a TNF-mediated disease, disorder, or condition, or a p38-mediated disease, disorder, or condition, in particular the allergic and non-allergic airways diseases, more particularly obstructive or inflammatory airways diseases, preferably chronic obstructive pulmonary disease.

Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors

Growing community of inventors

Sandwich, United Kingdom

Christopher Phillips